Partner with PolyGene in open scientific research calls
PolyGene is eager to collaborate on future projects to enhance biomedical research and development.
If you have a project idea for one of the open calls and if it involves the generation of genome engineering, please get in contact with us; depending on the detailed call text and your requirements, we will participate as a consultant, a partner, but also as a (co-)coordinator.
The new Horizon 2020 Societal Challenge 1 calls
The European Commission has recently published the 2019 Horizon 2020 Calls. PolyGene is actively looking to join consortia preparing proposals for the following topics:
SC1-BHC-01-2019: Understanding causative mechanisms in co- and multimorbidities
SC1-BHC-02-2019: Systems approaches for the discovery of combinatorial therapies for complex disorders
SC1-BHC-07-2019: Regenerative medicine: from new insights to new applications
SC1-BHC-14-2019: Stratified host-directed approaches to improve prevention, treatment and/or cure of infectious diseases
This will be the last funding round of the Horizon 2020 Programme. Let’s not miss the opportunity to advance European research together and bring new therapies to the market for the benefit of all patients!
Further details can be found at the EC Participant Portal
COST Action „European Epitranscriptomics Network” – Looking for Cooperations
This EU funded COST action EPITRAN hopes to understand the role of RNA modification in physiology and pathology and by that identify novel disease biomarkers and drug targets.
PolyGene is active member and recently participated in the kick-off meeting in Brussels.
Join us in the epitranscriptomic revolution.
EUROSTARS – Application closed
This call ended March 2017. Thanks for participating.
For a future Eurostars grant application we are looking for collaborative european partners with skills in
- Computational Chemistry and Molecular Modeling for in silico structure determination and protein-DNA binding optimization
- Protein Chemistry to set up innovative screening assays (e.g. EMSA, SPR) for DNA binding mutants with improved functional properties
PolyGene has developed powerful novel inducible systems based on the antibiotic macrolide and on the glucocorticoid hormone RU486/mifepristone..
To improve the prototypes in terms of tightness (low leaky expression in absence of inducer), high inducibility, reversibility, low toxicity of the inducing agent, high sensitivity, low toxicity of DNA elements of the induction system and high bioavailability of the inducer, we are searching for partners.
The final deliverable of the project will be a commercially available kit containing plasmids, cells, reagents for researchers from academia and industry allowing them to perform inducible (multi)gene expression studies in vivo.
Eurostars grant applications have one of the highest success rates compared to similar endeavors, and a supreme financial compensation. Find more information on Eurostars website.GET IN CONTACT